A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Summary

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

Timeline

Start

2022-04-28

Primary completion

2023-11-28

Completion

2023-11-28

Drugs

Indications